Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over ...

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced the closing of a $35 million ...

Hippo signalling is a cell signalling pathway that controls organ size. Activation of Hippo results in a series of phosphorylation events that culminate in the phosphorylation and cytoplasmic ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...

California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. The proceeds will support ...

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

In 2011 she moved to do her postdoc with Nicolas Tapon at the Cancer Research UK London Research Institute (now The Francis Crick Institute), where she worked on the regulation of tissue growth via ...

Janus kinase/signal transduction and transcription activation (JAK/STAT) pathways were originally thought to be intracellular signaling pathways that mediate cytokine signals in mammals. Existing ...